SCHEMBL6986566

SCHEMBL6986566

O=C(O)C1C=Nc2c(cc(F)c3cccnc23)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 7/20 0.39
KDM4E B2RXH2 5/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
PKM P14618 1/20 0.39
IDO1 P14902 1/20 0.39
RECQL P46063 1/20 0.39
TDO2 P48775 1/20 0.39
BLM P54132 1/20 0.39
CASP6 P55212 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SLC40A1 Q9NP59 5/20 0.38
MPI P34949 1/20 0.38
NPC1 O15118 2/20 0.34
ALOX12 P18054 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981101 0.85 L3MBTL1 (0.43) L3MBTL1KDM4EMEN1ALDH1A1LMNA
SCHEMBL6981252 0.83 L3MBTL1 (0.38) L3MBTL1KDM4EMEN1ALDH1A1LMNA
SCHEMBL6980560 0.78 MAPT (0.47) L3MBTL1KDM4EMEN1ALDH1A1LMNA
SCHEMBL1509598 0.77 LMNA (0.43) L3MBTL1KDM4EALDH1A1LMNAMAPT
SCHEMBL6985131 0.75 KDM4E (0.37) L3MBTL1KDM4EMEN1ALDH1A1LMNA
SCHEMBL5566400 0.70 KMT2A (0.35) L3MBTL1KDM4EMEN1ALDH1A1LMNA
SCHEMBL967454 0.69 L3MBTL1 (0.39) L3MBTL1KDM4EALDH1A1LMNAMAPT
SCHEMBL5819956 0.69 DAO (0.36) L3MBTL1KDM4EMEN1LMNAPOLB
SCHEMBL7081619 0.69 CES2 (0.31)
Hydrochloric Acid SCHEMBL10655026 0.69 KMT2A (0.34) L3MBTL1KDM4EMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP claimed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO claimed
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 L3MBTL1 2168/4885KDM4E 162/4885MEN1 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.